Literature DB >> 12055630

Linking innate and acquired immunity: divergent role of CD46 cytoplasmic domains in T cell induced inflammation.

Julien C Marie1, Anne L Astier, Pierre Rivailler, Chantal Rabourdin-Combe, T Fabian Wild, Branka Horvat.   

Abstract

CD46 is a widely expressed transmembrane protein that was initially identified as binding and inactivating C3b and C4b complement products. We used mice that were transgenic for one of two human CD46 isoforms that differ in their cytoplasmic domains (termed CD46-1 and CD46-2) to analyze the effect of CD46 stimulation on the immune response. We show here that CD46 can regulate inflammatory responses, either by inhibiting (CD46-1) or increasing (CD46-2) the contact hypersensitivity reaction. We found that engagement of CD46-1 or CD46-2 differentially affected CD8(+) T cell cytotoxicity, CD4(+) T cell proliferation, interleukin 2 (IL-2) and IL-10 production as well as tyrosine phosphorylation of Vav in T lymphocytes. These results indicate that CD46 plays a role in regulating the T cell induced inflammatory reaction and in fine-tuning the cellular immune response by bridging innate and acquired immunity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12055630     DOI: 10.1038/ni810

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  64 in total

1.  CD46 engagement on human CD4+ T cells produces T regulatory type 1-like regulation of antimycobacterial T cell responses.

Authors:  Steven M Truscott; Getahun Abate; Jeffrey D Price; Claudia Kemper; John P Atkinson; Daniel F Hoft
Journal:  Infect Immun       Date:  2010-10-04       Impact factor: 3.441

2.  The complement receptor CD46 tips the scales in T(H)1 self-control.

Authors:  Christian M Karsten; Jörg Köhl
Journal:  Nat Immunol       Date:  2010-09       Impact factor: 25.606

Review 3.  T-cell stimulation and regulation: with complements from CD46.

Authors:  Claudia Kemper; James W Verbsky; Jeffrey D Price; John P Atkinson
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

4.  Ligation of the cell surface receptor, CD46, alters T cell polarity and response to antigen presentation.

Authors:  Jane Oliaro; Anupama Pasam; Nigel J Waterhouse; Kylie A Browne; Mandy J Ludford-Menting; Joseph A Trapani; Sarah M Russell
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-20       Impact factor: 11.205

5.  Complement-induced regulatory T cells suppress T-cell responses but allow for dendritic-cell maturation.

Authors:  Winfried Barchet; Jeffrey D Price; Marina Cella; Marco Colonna; Sandra K MacMillan; J Perren Cobb; Paul A Thompson; Kenneth M Murphy; John P Atkinson; Claudia Kemper
Journal:  Blood       Date:  2005-10-20       Impact factor: 22.113

6.  Levels of expression of complement regulatory proteins CD46, CD55 and CD59 on resting and activated human peripheral blood leucocytes.

Authors:  Stephen E Christmas; Claudia T de la Mata Espinosa; Deborah Halliday; Cheryl A Buxton; Joanne A Cummerson; Peter M Johnson
Journal:  Immunology       Date:  2006-09-26       Impact factor: 7.397

7.  CD46-utilizing adenoviruses inhibit C/EBPbeta-dependent expression of proinflammatory cytokines.

Authors:  Milena Iacobelli-Martinez; Ronald R Nepomuceno; Jodi Connolly; Glen R Nemerow
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

8.  Presenilin/gamma-secretase cleaves CD46 in response to Neisseria infection.

Authors:  Nathan J Weyand; Christine M Calton; Dustin L Higashi; Kristen J Kanack; Magdalene So
Journal:  J Immunol       Date:  2009-12-16       Impact factor: 5.422

9.  A recombinant adenovirus type 35 fiber knob protein sensitizes lymphoma cells to rituximab therapy.

Authors:  Hongjie Wang; Ying Liu; Zong-Yi Li; Xiaolong Fan; Akseli Hemminki; André Lieber
Journal:  Blood       Date:  2009-11-12       Impact factor: 22.113

Review 10.  T-cell regulation by CD46 and its relevance in multiple sclerosis.

Authors:  Anne L Astier
Journal:  Immunology       Date:  2008-04-02       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.